Imatinib in Adult Patients With Metastatic Ocular Melanoma

Study acronym: O-Mel-Inib
StatusTerminated
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Mar 2007 to Nov 15, 2009v4
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Recruiting to Terminated Sponsor's reason: Study stopped at the end of the first stepv2 Show 5 more changesShow less
    • Enrollment target: 32 to 13
    • Study sites: 10 to 12
    • Primary completion date: Mar 2007
    • Study completion date: Jan 2009 to Mar 2007
    • Collaborators expanded, about 5 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Centre Oscar Lambret
100 trials monitored
See 2 trials at risk
Melanoma
1,097 trials monitored
See 63 trials at risk
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.
Trial Details
NCT Number NCT00421317
Lead Sponsor Centre Oscar Lambret
Collaborators: Novartis, National Cancer Institute, France
Conditions
(from sponsor)		 Melanoma
Related terms Melanoma
Enrollment 13 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov